Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bought 5,05
BBRG To Da 4,9
BBRG
Insiders Have Increased Positions in: Bravo Brio Restaurant Group, Inc. (NASDAQ:BBRG)
.
http://www.engelwooddaily.com/insiders-have-increased-positions-in-bravo-brio-restaurant-group-inc-nasdaqbbrg-3/781921/
.
https://www.google.com/finance?q=NASDAQ%3ABBRG&ei=iw7hV5nXCoigsgH10IWICQ
BBRG
Insiders Have Increased Positions in: Bravo Brio Restaurant Group, Inc. (NASDAQ:BBRG)
.
http://www.engelwooddaily.com/insiders-have-increased-positions-in-bravo-brio-restaurant-group-inc-nasdaqbbrg-3/781921/
.
https://www.google.com/finance?q=NASDAQ%3ABBRG&ei=iw7hV5nXCoigsgH10IWICQ
Ouch .20 ?
Elite today is IN THE BEST FINANCIAL SHAPE ever in her history. We continue to grow the genetic business and the ADT business and we will file an application every quarter starting with this quarter Q3, 2016 "
“After three straight years of record revenues, Fiscal 2017 begins with another strong quarter with revenues continuing their upward trend,”
"..FDA made no comment about Elite’s technology because it works and it’s solid. They made no comment on the human abuse liability studies because again they were solid and they work; or with the withdrawal study or the efficacy study – the Bunionectomy. This is great news for Elite’s ADT platform. There is no effect on Elite’s ER formulations because as I said their concern is that this is instant release and it’s used as needed so if you take it when you need it and you just ate a lot of fat then it affects you but for the ER they understand that a patient can plan to take it in the morning and then – before breakfast and before dinner. "
Shares in Oversold Area: . (NASDAQ:BBRG)
Bravo Brio Restaurant Group, Inc
" Elite today is IN THE BEST FINANCIAL SHAPE ever in her history. We continue to grow the genetic business and the ADT business and we will file an application every quarter starting with this quarter Q3, 2016 "
So, we do not know what is Tmax delay extent for SequestOx.
Is this Tmax issue also the same problem with ER products?
Maybe ELTP should first continue with ER formulation with some partner and continuously solve problem with Tmax SequestOx...
Consolidated revenues for Fiscal 2016 were a record $12.5 million, an increase of approximately 150% over revenues of the prior year. This increase is due to across-the-board increases in both manufacturing revenues and license fees. Manufacturing revenues more than doubled from $3.8 million last year to $8.0 million in Fiscal 2016. The growth was from a strong, sustained and broad expansion in the sales of Elite's product revenues. License fees more than tripled from $1.1 million last year to $4.5 million in Fiscal 2016
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=81846&GoTopage=1&Category=2163&BzID=2258&t=2054&G=939
"..FDA made no comment about Elite’s technology because it works and it’s solid. They made no comment on the human abuse liability studies because again they were solid and they work; or with the withdrawal study or the efficacy study – the Bunionectomy. This is great news for Elite’s ADT platform. There is no effect on Elite’s ER formulations because as I said their concern is that this is instant release and it’s used as needed so if you take it when you need it and you just ate a lot of fat then it affects you but for the ER they understand that a patient can plan to take it in the morning and then – before breakfast and before dinner. "
Green day would be nice, today, tomorrow, after so much panic selling
Buy Low
Elite today is IN THE BEST FINANCIAL SHAPE ever in her history. Elite has the best talent and best pipeline, ever. We continue to grow the genetic business and the ADT business and we will file an application every quarter starting with this quarter Q3, 2016
CC and another great QUARTERLY REPORT in 2 weeks
UNDERVALUED
Eltp GENERIC PRODUCTS
http://www.elitepharma.com/products/
Consolidated revenues for Fiscal 2016 were a record $12.5 million, an increase of approximately 150% over revenues of the prior year. This increase is due to across-the-board increases in both manufacturing revenues and license fees. Manufacturing revenues more than doubled from $3.8 million last year to $8.0 million in Fiscal 2016. The growth was from a strong, sustained and broad expansion in the sales of Elite's product revenues. License fees more than tripled from $1.1 million last year to $4.5 million in Fiscal 2016
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=81846&GoTopage=1&Category=2163&BzID=2258&t=2054&G=939
Eltp BRANDED PIPELINE
http://www.elitepharma.com/pipeline-branded/
RSI(14) 21,67
Wm %R (14) -97,14
GO namtae, GO !!
July 15th, probably
Weak hands not waiting for transcript
Wonder how high we'll go today!
The leading market experts have placed a mean price target of $5.00 on Christopher & Banks Corporation (NYSE:CBK) stock
http://www.equitiesfocus.com/stock-to-watch-christopher-banks-corporation-nysecbk/166243/
Elite Pharmaceuticals (OTCMKTS:ELTP) On The Verge Of Major Developments
http://www.insiderfinancial.com/elite-pharmaceuticals-otcmktseltp-on-the-verge-of-major-developments/114213/
*****************ELTP******************
.
Near term Goals :
ELI 200 submission in 2015 & approval in 2016
Continuing manufacturing facility´s expansion, equipment upgrade and staffing
- Loxapine & Dantrolene launch
- Filling two more opioid products in 2016
- ELI 200 product launch with marketing partner
Revenue growth from niche generics and first ADF product
Profitability
Base generic business profitable in 2016
R&D costs supported with ELI 200 in 2017
Elite Pharmaceuticals, Inc. Reports Strong Growth for Second Quarter of Fiscal Year 2016
http://ir.elitepharma.com/profiles/investor/ResLibraryView.asp?ResLibraryID=79776&BzID=2258&t=1948&g=939&Nav=0&LangID=1&s=0
****ELTP****NDA FILIING BY YEARS END
Thanks Couch, GLTU and all ELTP investors !
.
ELTP_ Elite Pharmaceuticals Announces Positive Top-Line Results From A Pivotal Phase 3 Study For Abuse-Deterrent Opioid ELI-200
.
Near term Goals :
ELI 200 submission in 2015 & approval in 2016
Continuing manufacturing facility´s expansion, equipment upgrade and staffing
- Loxapine & Dantrolene launch
- Filling two more opioid products in 2016
- ELI 200 product launch with marketing partner
Revenue growth from niche generics and first ADF product
Profitability
Base generic business profitable in 2016
R&D costs supported with ELI 200 in 2017
*****************ELTP******************
.
ELTP_ Elite Pharmaceuticals Announces Positive Top-Line Results From A Pivotal Phase 3 Study
For Abuse-Deterrent Opioid ELI-200
.
Near term Goals :
ELI 200 submission in 2015 & approval in 2016
Continuing manufacturing facility´s expansion, equipment upgrade and staffing
- Loxapine & Dantrolene launch
- Filling two more opioid products in 2016
- ELI 200 product launch with marketing partner
Revenue growth from niche generics and first ADF product
Profitability
Base generic business profitable in 2016
R&D costs supported with ELI 200 in 2017
***************ELTP****************
.
ELTP_ Elite Pharmaceuticals Announces Positive Top-Line Results From A Pivotal Phase 3 Study
For Abuse-Deterrent Opioid ELI-200
.
Near term Goals :
ELI 200 submission in 2015 & approval in 2016
Continuing manufacturing facility´s expansion, equipment upgrade and staffing
- Loxapine & Dantrolene launch
- Filling two more opioid products in 2016
- ELI 200 product launch with marketing partner
Revenue growth from niche generics and first ADF product
Profitability
Base generic business profitable in 2016
R&D costs supported with ELI 200 in 2017
Near term Goals
ELI 200 submission in 2015 & approval in 2016
Continuing manufacturing facility´s expansion, equipment upgrade and staffing
- Loxapine & Dantrolene launch
- Filling two more opioid products in 2016
- ELI 200 product launch with marketing partner
Revenue growth from niche generics and first ADF product
Profitability
Base generic business profitable in 2016
R&D costs supported with ELI 200 in 2017
Estimated Study Completion Date: August 2015
then you are in BIG trouble guys!
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=116337894
ELTP_ GET IN AT THE BOTTOM!!!!
$15 million in milestones timed and frontloaded as they are, provides us with much needed funding for the continued and expedited development of additional Abuse-Deterrent opioid products
.
Just a few more quick points on our financials, if you look at our cash flow statement you’ll see we’re reporting an operating cash burn of $15.1 million and also our P&L statement shows $14.8 million in R&D expense. So, if you put these two numbers together, this statement show that the cash burn is due to the R&D costs, not really a surprise there. These R&D costs are however starting to really pay off for us.
.
Our working capital was $7.3 million, our cash-on-hand was $7.5 million and all of our liabilities including the New Jersey Economic Development bonds were in compliance. So all of the defaults of the past has been resolved, they are all in the past.
.
We had record revenues for the second straight year, we booked $5 million for the first time, our generic products continue to perform well and we still have a robust pipeline to provide future increases and expansion.
http://investorshub.advfn.com/boards/board.aspx?board_id=15170
$ELTP...looking good!...
ELTP_ Elite Pharmaceutical[color=green][/color]
$15 million in milestones timed and frontloaded as they are, provides us with much needed funding for the continued and expedited development of additional Abuse-Deterrent opioid products
.
Just a few more quick points on our financials, if you look at our cash flow statement you’ll see we’re reporting an operating cash burn of $15.1 million and also our P&L statement shows $14.8 million in R&D expense. So, if you put these two numbers together, this statement show that the cash burn is due to the R&D costs, not really a surprise there. These R&D costs are however starting to really pay off for us.
.
Our working capital was $7.3 million, our cash-on-hand was $7.5 million and all of our liabilities including the New Jersey Economic Development bonds were in compliance. So all of the defaults of the past has been resolved, they are all in the past.
.
We had record revenues for the second straight year, we booked $5 million for the first time, our generic products continue to perform well and we still have a robust pipeline to provide future increases and expansion.
[color=greenELTP Elite pharmaceuticals[/color]
$15 million in milestones timed and frontloaded as they are, provides us with much needed funding for the continued and expedited development of additional Abuse-Deterrent opioid products
.
Just a few more quick points on our financials, if you look at our cash flow statement you’ll see we’re reporting an operating cash burn of $15.1 million and also our P&L statement shows $14.8 million in R&D expense. So, if you put these two numbers together, this statement show that the cash burn is due to the R&D costs, not really a surprise there. These R&D costs are however starting to really pay off for us.
.
Our working capital was $7.3 million, our cash-on-hand was $7.5 million and all of our liabilities including the New Jersey Economic Development bonds were in compliance. So all of the defaults of the past has been resolved, they are all in the past.
.
We had record revenues for the second straight year, we booked $5 million for the first time, our generic products continue to perform well and we still have a robust pipeline to provide future increases and expansion.